Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Diseases 1

Interventions

fludarabine 4ibrutinib 2Rituximab 2Cyclophosphamide 2Alemtuzumab 2venetoclax 1ruxolitinib 1ponatinib 1ethanolamine oleate 1enzalutamide 1durvalumab 1dacetuzumab 1blinatumomab 1Valganciclovir 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Tacrolimus 1Sulfamethoxazole 1Stem Cell Transplantation 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Pentetic Acid 1Lenalidomide 1Ganciclovir 1Ethanol 1Edetic Acid 1CA-4948 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoproliferative Disorders × dacetuzumab × Clear all
NCT00283101 2014-12-18

A Safety Study in Patients With Chronic Lymphocytic Leukemia

Seagen Inc.

Phase 1/2 Completed
12 enrolled
LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡